The field of tissue engineering is developing biomimetic biomaterial scaffolds that are showing increasing therapeutic potential for the repair of cardiovascular tissues. However, a major opportunity exists to use them as 3D in vitro models for the study of cardiovascular tissues and disease in addition to drug development and testing. These in vitro models can span the gap between 2D culture and in vivo testing, thus reducing the cost, time, and ethical burden of current approaches. Here, we outline the progress to date and the requirements for the development of ideal in vitro 3D models for blood vessels, heart valves, and myocardial tissue. Reviews POST SCREEN Corresponding author:. O'Brien, F.J. (fjobrien@rcsi.ie) 6 These authors contributed equally to this work. 1359-6446/ß
Introduction
Cardiovascular disease (CVD) represents a major healthcare and economic burden and is currently the leading cause of noncommunicable deaths worldwide [1, 2] . The diseases of hypertension, heart failure, cardiac hypertrophy, cardiomyopathy, endocarditis, thrombosis, atherosclerosis, valvular regurgitation, and stenosis resulted in US$320 billion expenditure in healthcare costs in 2011 in the USA alone [2] . Despite the staggering annual mortality of 17.5 million in 2012, the number of deaths has steadily declined since the 1970s as a result of scientific advances [1, 3] . Increased funding for research in the cardiovascular field has been vital to decelerate this progression and, with an aging population, this research needs to continue to discover and develop new therapeutics, medical devices, bioengineered replacement tissues, and surgical solutions.
Research into CVD is typically carried out using 2D in vitro culture conditions that, although relatively cheap and simple, are a non-ideal environment to study cellular phenotype and behaviour ( Fig. 1) [4, 5] . The benefit of in vitro 3D models is their improved physiological relevance and, although imperfect, they could serve as a bridge between 2D cultures and in vivo models, to determine the mechanism and efficacy of targeted formulations and devices [5] . While preclinical animal models continue to serve as a key efficacy and safety requirement for the translation of therapeutics, the degree of reliability achieved in reproducing human pathophysiology in animal models is frequently inadequate [6] . This undoubtedly contributes to the low success rate in developing efficient and safe therapies [7, 8] . Additionally, in recent years, we have witnessed an increased awareness of the ethical implications of the use of animals for medical research, encouraged by funding bodies and editors, and represented by the concepts of the 3Rs (replacement, reduction, and refinement) principle. These limitations in the use of both animal models and classical in vitro 2D models have propelled the expansion of research into new in vitro 3D cardiovascular models that allow for greater control of variables and also a shortened experimental time compared with in vivo models [9] . Ideal 3D models need to replicate not only the anatomical macrostructure, but also the tissue and cell-level microstructures, including appropriate cell types, biomimetic extracellular matrix (ECM) arrangement, and appropriate physiological cues. This will ensure greater precision and reliability for translation, while reducing the number of animals used in development ( Fig. 1) .
Although preclinical animal models are a necessary step towards the regulatory approval of new devices and pharmaceutics, in vitro testing can reduce translation costs and time and help to identify the mechanism of action together with any associated risks. Although preclinical drug screening is typically achieved with mouse models, the human cardiac physiological response to drugs has been shown to be markedly different to that in mice, leading to relatively high failure rates during the clinical trial phase. Translating a drug from a US Food and Drug Administration (FDA)-classed new molecular entity (NME) to approved clinical product is estimated to cost between US$0.8 billion and US$1.8 billion and typically spans 8-12 years [15] , not including the initial years of investment in basic research leading to initial drug discovery. Little is known about the safety and offtarget effects of NMEs before human clinical trials resulting from phylogenetic differences between humans and animal models. This has resulted in the catastrophic failure of many Phase I drug trials and further highlights the inadequacies of current in vitro testing, which often are not representative of the in vivo preclinical environment, let alone the clinical situation in humans. Along similar lines, medical device development is estimated to cost between US$31 million and US$94 million (depending on device risk) before clinical testing [16] and, although the unwanted effects of devices tend to be more mechanical, combination products still need a representative in vitro testing platform. Indeed, simpler medical devices can also benefit from an improved in vitro testing environment, where device long-term performance, and biocompatibility testing can be tested in a more Importance of the microenvironment to cardiovascular cellular phenotypes. (a) Biomechanical influences within the 3D microenvironment of the cell affect the cellular phenotype. (b) This is illustrated within native adult cardiomyocytes by the selective localisation and/or function of their cellular proteins, which maintain cell structure, intercellular communications, intracellular pH regulation, and Ca 2+ handling. (c) Conventional static 2D culture of adult myocytes fails to preserve the adult phenotype and (d) induces progressive dedifferentiation to a foetal phenotype. (e) The functional phenotype can be rescued, for example, by replicating the physiological strain in cultured rat neonatal cardiomyocytes (i,ii) or by application of shear stress on cultured human aortic endothelial cells (iii,iv). Reproduced, with permission, from [10] (b), [11] , (c), [12] (d), and [13, 14] (e).
characteristic way, while being fully controllable, accessible, and measurable. The rapid expansion of the field of cardiovascular tissue engineering has seen the development of biomaterials and neotissues with the innate capacity to grow and remodel in vitro and, as such, can be utilised as platforms to assess pharmaceutics and devices before preclinical work. Currently used in vitro 3D models include spheroids, hydrogels, ECM-derived matrices, scaffolds, and decellularised tissues and/or organs [5] . For the treatment of CVD, tissue engineering has focussed on bioengineered vessels, valves, and regenerated myocardial tissue, with the additional potential to enhance their regenerative capacity through the incorporation of drugs, genetic tools, and cells. Thus, biomaterials for tissue engineering provide templates upon which multiple cell types can be cultured, and can combine genes [17] and growth factors together with ECM constituents [18, 19] . Mechanical and architectural properties of biomaterials can be easily refined, from varying their stiffness to their porosity and pore size [18, 20, 21] . In addition, incorporation of surface-binding ligands and antibodies can encourage specific cell attachment, while dynamic forces can be applied to these biomaterials, to elucidate responses also observed in vivo [22] . The toolset available to bioengineers has now reached a point where the in vitro replication of native tissues is achievable through innovative biofabrication techniques, advanced cell manipulation, and the application of physiologically relevant environments through bioreactor technologies.
Here, we focus on three examples of potential 3D models of cardiovascular tissue: vascular grafts, cardiac valves, and myocardial tissue. It is envisioned that these 3D models will provide test beds for advanced drug and device testing in addition to disease modelling and precision medicine screening [22] . We outline the parameters that should be considered in developing a true in vitro model for each tissue and describe recent advances in each area.
3D in vitro models of blood vessels
Tissue-engineered blood vessels (TEBVs) hold great promise clinically, where they could be utilised for coronary artery bypassing, peripheral artery disease, or as an arteriovenous graft for haemodialysis access [23] . Strides towards achieving these goals have been made using several distinct approaches to TEBV development with both autologous [24] and allogeneic cells [23, 25] , and matured through the application of physiological haemodynamic forces within pulsatile bioreactors. The native blood vessel structure comprises a multi-lamellar architecture with a distinct arrangement of endothelial cells (ECs), smooth muscle cells (SMCs), and fibroblasts, which together maintain a normal functional vessel. Replication of native vessels can be achieved by generating biomimetic scaffolds comprising native polymers, such as collagen and elastin [18] , in a complex 3D tubular architecture [26] , and the correct spatial arrangement of vascular cells [27] (Fig. 2a,b) . Interestingly, the commercial approach for implantable TEBVs by some of the leading companies in the field, including Humacyte Atherosclerotic disease progression and in vitro device testing. The healthy vessel wall (a) is infiltrated by macrophages, which begin to form foam cells and initiate the degenerative cascade, which eventually results in an unstable atherosclerotic lesion (b). The complex process of atherosclerotic lesion progression has proven difficult to replicate in vitro. Radiographic image of a stent deployed within a blood vessel mimic (v) [28] . Abbreviations: EC, endothelial cells; SMC, smooth muscle cells.
Inc. and Cytograft Tissue Engineering Inc, has progressed towards growing TEBVs in vitro and then decellularising these TEBVs to reduce costs and complexity, and to ease the regulatory pathway. The advances made towards the realisation of a clinically available vascular graft have left the field with the knowledge and toolsets required to generate high-fidelity vascular analogues in vitro that could also be used preclinically in vitro.
One of the initial areas of interest for in vitro TEBV models was for pharmacological studies. Nicolas L'Heureux, one of the pioneers of TEBVs, demonstrated in 1998 the ability to create triplelayered grafts [28] , before generating individual vascular tissue layers for pharmacological studies of contraction [29] . These medial layer equivalents were generated from human vascular SMCs and were shown to be responsive to multiple vasoconstrictors (e.g. histamine, ATP, bradykinin, and UTP) in a concentration-dependent manner. This reduction in complexity for a pharmacological study was an interesting approach because it allowed the physiological response of a single cell type and/or tissue layer to be determined. A similar approach was utilised to create medial layer-equivalent TEBVs that maintained the subtle differences in receptor expression and response to endothelin as the native vessels from which the cells were extracted [30] .
The innermost layer of blood vessels, the tunica intima, is lined with ECs, a vital component to maintain haemostasis and control vascular permeability. However, the deployment of intravascular devices, such as stents, is known to damage the EC lining of vessels and so all the device deployment studies to date have first focused on generating a model vessel containing a confluent EC monolayer [31] [32] [33] (Fig. 2c ). While these studies used EC monolayers that were preconditioned via a bioreactor flow loop system to simulate in vivo haemodynamics, the underlying vessels utilised thus far for device testing have been of a synthetic nature, such as expanded polytetrafluoroethylene [31, 32] or silicone [33] . Consequently, there exists a need for an in vitro TEBV model that can not only simulate EC damage during device deployment, but also contains a SMC-seeded tunica media (middle layer) to simulate restenosis, the narrowing of vessels, which is commonly caused by neointimal hyperplasia of SMCs because of device deployment [34] .
In conjunction with device testing, the use of a TEBV as an in vitro model might also be a useful platform to study CVDs, such as atherosclerosis, which alone is responsible for 67.8% of CVDrelated deaths [35] . Although our ability to combat the clinical manifestations of atherosclerosis with advanced treatment modalities has resulted in reduced disease mortality [36] , the prevention and reversal of the disease itself remains unfulfilled. Atherosclerosis is a complicated disease with the pathogenesis involving ECs, SMCs, lipoproteins, and macrophages over a time period often spanning decades ( Fig. 2a,b ). Early in vitro models of the disease utilised permeable membranes for the co-culture of ECs and SMCs, and successfully demonstrated the transmigration of monocytes across the EC layer and uptake of low-density lipoprotein (LDL) to form foam cells [37] . Although these were important steps in the field, they do not accurately represent the 3D environment of native vasculature cells. Some progress towards a biomimicking atherosclerotic model was made with the creation of flat 3D fibrin gels, which were capable of long-term culture and facilitated the formation of foam cells [38] . Utilising this model enabled examination of LDL-induced expression of interleukin 8, a neutrophil chemokine, by SMCs and the subsequent recruitment of neutrophils into the subendothelial space, a previously unproven association [39] .
An additional important factor in the progression of atherosclerosis is the effect of flow-induced shear stress, and cyclical strain [40] . A 3D tubular architecture is required to impart these forces accurately, in conjunction with pulsatile flow bioreactors, which can control the fluid forces applied. Such a model has been shown to be capable of generating the first 3D tubular TEBV, which mimicked the early stages of atherosclerosis under dynamic culture conditions [41] . With few research groups seemingly tackling the issue of creating high-fidelity atherosclerotic disease models, the progress in the field has understandably been slow to date. Furthermore, because vulnerable plaque lesions take decades to form naturally in vivo, the next step in this research must be to drastically accelerate the lesion-forming process in vitro (Fig. 2b) to allow for analysis of the parameters that affect the progression of this disease. Having a representative 3D model of atherosclerosis would allow the in vitro testing of therapeutics that could directly target lesions in a controlled and measurable way. In fact, the targeting of atherosclerotic lesions via nanoparticles has recently been modelled in vitro with a microfluidic system containing an atherosclerotic endothelium with controlled permeability, opening the field to further use of these models for modelling targeted drug delivery [42] . Transferring this type of testing into a larger 3D in vitro model is possible using the techniques developed for TEBVs.
Although great advances have been made in the field towards realising the use of TEBVs as implantable grafts to replace diseased or damaged tissue, the tissue complexity achieved is far beyond that utilised for device testing and disease modelling. This highlights the disconnect between the in vitro models generated, which display poor physiological relevance, and those that the field is undoubtedly capable of generating for use as implantable TEBVs.
3D in vitro models of heart valves
With an increasing aging population and no proven pharmaceutical therapies to decelerate it, valvular disease is predicted to become the next global epidemic [43] , with a prevalence of disease observed in aortic and mitral valves. A representative in vitro 3D model of aortic heart valves would help elucidate the mechanisms driving calcific aortic valvular disease (CAVD), a disease that affects 2.8% of the population [2] , or endocarditis (bacterial and viral), both of which have limited treatment options [44] . Mitral valves also have calcification of their chordae tendineae, annulus, and the valve leaflets, requiring valve repair or replacement. Tissue-engineering strategies for heart valves are varied, with a multitude of cell sources [45] , scaffold materials [19] , and fabrication strategies currently under investigation [46] [47] [48] [49] [50] . However, for a tissue-engineered valve to serve as an in vitro 3D model, ECMderived scaffold materials and native valvular cells would be a requisite starting point, followed by biomimetic ECM structure and appropriate mechanical properties. Many tissue-engineered valves utilise cell sources such as umbilical vein cells and mesenchymal stem cells [45] , cell types that would be suboptimal in an in vitro 3D model of the valve, but have advantages for engineered autologous tissues because of their ability to differentiate and act as valvular-type cells. However, many of the sophisticated valve scaffolds that have been developed through tissue engineering could be easily populated with more representative cells for an in vitro model. Here, we concentrate on the aortic valve, because most tissue-engineering strategies that could be used as in vitro models are focussed on this structure. The highly organised configuration of the aortic valvular ECM prevents regurgitation of blood through coaptation of its three cusps or leaflets, each of which has the same trilayered microstructure. The fibrosa, spongiosa, and ventricularis layers occupy an overall thickness of approximately 1 mm and comprise collagen, elastin, and glycosaminoglycans in a specific arrangement (Fig. 3 ). Valvular interstitial cells (VICs) occupy the tissue layers, maintaining valve homeostasis through regulation of cellular proliferation and tissue remodelling. Although VICs are a fibroblastic cell type, they have five different phenotypes, and can convert from one form to another [51] . The nonthrombogenic interface of the valves between the blood and VICs is maintained by valvular endothelial cells (VECs). At a basic structural and functional level, the valvular and vascular endothelium appear similar; however, comparisons have identified hundreds of significantly different genes [52] . In dynamic culture, their response to shear and pressure is different and their transcriptional gene expression profile also differs when exposed to the same mechanical environment [52] [53] [54] . VECs regulate the activation of VICs through mechanotransduction, nitric oxide, vasodilatory prostanoids, and endothelin 1 [51] .
In vitro, individual cellular components of the complex valve structure have been examined in isolation using 3D models, with an aim of understanding the mechanisms driving CAVD. The expression of growth factors by VICs has been examined at the edge of a damaged VIC layer using an 'in vitro wound model' [55] , advancing understanding of VICs in a simple model system. 3D structures, such as PEG hydrogels, have been used to characterise VICs in isolation [56, 57] and the reaction of VIC to substrate stiffness [57] [58] [59] [60] . However, without the interactions of VECs within the correct ECM structure, these 3D models are limited.
The creation of a layered co-culture system with the physiological ECM components and structure is challenging, although simple VIC/VEC co-culture studies have been carried out. An interesting method using magnetic levitation was proposed by Grande-Allen's group [63] , who also proposed a synthetic PEG hydrogel system to encourage layer-specific cell growth [64] . Collagen gels incorporating glycosaminoglycans have been used in both single cell cultures and co-cultures to investigate the interactions of ECM proteins with cells [65] [66] [67] [68] . However, without the correct ECM structure found in vivo, the addition of these matrix components facilitates limited learning, because their structure, mechanical properties, and orientation are not considered.
The introduction of dynamic culture is a necessary parameter to investigate cardiovascular cell interactions, but further complicates any experimental setup and, as such, limited models have been developed to date. Collagen hydrogels have been used to assess VIC response to cyclic strain [69] and VIC/VEC response to shear stress [70, 71] but again, because of the lack of a biomimetic ECM structure, these studies are limited. Other dynamic studies focussed on the development of tissue-engineered valve replacements; however, these studies have not utilised VICs [72] because, for tissue-engineered valves, this cell source would be unavailable when developing valves for patients. However, there is the potential to use these scaffold arrangements to study VIC-VEC interactions in dynamic culture. A porous fibrin-collagen-glycosaminoglycan scaffold was recently developed [20] that shows potential for use as a platform to examine VIC-VEC interactions in dynamic culture. This model system, created from natural materials, has mechanical properties that can be altered as per experimental needs, can be formed into any shape, used within a dynamic environment, and can facilitate homogenous VIC distribution while maintaining a monolayer of VECs [73] .
CAVD pathogenesis is far from fully understood; it is hypothesised to result from both injury to the valve and the subsequent activation of cells to repair the injury, while also involving the reactivation of developmental processes, such as the endothelialto-mesenchymal transformation (EMT) [74] . A complete understanding of CAVD will allow for the development of suitable smallmolecule/drug treatment options for this disease. Representative 3D models of the aortic valve can elucidate that knowledge 
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FIGURE 3
The native aortic valve structure is multi-layered and anisotropic. This structure must be replicated in an in vitro 3D model to ensure correlation with the structure of the native valve. (a) The aortic valve leaflet comprises a distinct extracellular matrix (ECM) trilayered structure that (b) aligns and crimps to enable opening of the valve during systole. During diastole, the valve cusp sustains a large pressure difference across each side of the cusp and the ECM is strained to sustain this force. The layered structure of the valve is shown here with the fibrosa (f ), spongiosa (s), and ventricularis (v) having a distinct morphology with the valvular endothelial cells covering the ventricular and aortic side of the valve. Reproduced, with permission, from [61, 62] .
through the identification and understanding of cellular and ECM changes in early disease states. This could lead to use of 3D models for the controlled, advance screening of various treatments to address the changes seen in the diseased state. These treatments might range from small-molecule/drug treatments to devices, and a suitable 3D model would be an invaluable tool for assessment of these innovations. Initial observations on individual cell layers have shown interactions between serotonergic medications and the development of valvular heart disease [75] . Similarly, the mutations in the signalling and transcriptional regulator NOTCH 1 have been widely investigated because of the association between NOTCH 1 and a range of developmental aortic valve anomalies [76, 77] . Although many of these developmental studies are performed in vivo, the use of an in vitro 3D model with correct ECM architecture and human cells could progress knowledge and lead to the identification of a treatment for CAVD. Modification of the geometry used can allow optimisation for pulmonary, mitral, and tricuspid valves, enabling examination of more individual valvespecific conditions. Given the distinctiveness of valvular cells, the architecture of the valve itself, and the haemodynamic forces experienced by the tissue, a complete 3D model of the aortic valve can only be found in vivo, and explanted human and porcine valves have been studied to understand cellular dysfunction in both aortic and mitral valves [78, 79] . The next step is to have a representative in vitro 3D model to facilitate research into the causes and treatment of valve calcification, which would accelerate progress in combating this increasingly prevalent disease.
3D in vitro models of myocardial tissue
Modelling of cardiac tissue response in vitro is important because it enables the examination of CVD and potential drug responses before progressing to costly clinical trials. The myocardium is involved in the propagation of electrical signals and also in force generation through the cardiomyocyte-rich tissue and so can be considered a functional unit of the heart wall. Clinical manifestations of myocardial loss and/or dysfunction are traditionally observed after ischaemic events, such as myocardial infarction, resulting in the loss of functionally viable myocardium, which can lead to the downward spiral to heart failure.
2D monolayers of cardiomyocytes have been used successfully to estimate drug-induced apoptosis and cardiac tissue damage and/or breakdown (troponin and lactate dehydrogenase release) [80] . However, these studies have been performed using static cultures of immature, neonatal cardiomyocytes, which are not representative of the adult, fully differentiated, cell. In addition, it is widely known that adult cardiomyocytes dedifferentiate and do not survive medium-term culture (Fig. 1 ). Moreover, acquired or inherited cardiomyopathies are often characterised by impaired functional characteristics, with cardiomyocyte contractile forces and kinetics helping to determine final ejection fractions. Therefore, 3D myocardium models are an important toolset with which to determine the mechanism of action of cardiac drugs, potential pro-arrhythmic effects of drugs, protein knockdown studies, in conjunction with heart disease modelling.
Tiburcy et al. [81] showed that 3D culture can recapitulate suitable environmental conditions to model hypertrophic cardiac growth by inducing terminal differentiation of neonatal rat cardiomyocytes and remodelling of a collagen type I-based hydrogel. Further advancement of collagen hydrogel-based models has been achieved by moulding microtissues around microfabricated silicone posts (Fig. 4a,b) , where the tissue contraction force generation can then be determined through the deflection of the silicone posts [82] . Although these studies utilised rat neonatal cardiomyocytes, a more promising approach might be the creation of a human pluripotent stem cell-based model to generate adult human cardiomyocytes. Thavandiran et al. [83] reported the ability to create cardiac microtissues using human embryonic stem cells,
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Drug Discovery Today Volume 00, Engineering functional cardiac microtissues and simulation stress-induced maturation. (a) Engineered cardiac microtissues comprising neonatal mouse cardiomyocytes in a collagen I hydrogel that was contracted around polydimethylsiloxane microposts in a uniaxial or biaxial configuration. (b) Collagen (green) and cell (red) orientation during maturation was then tracked via fluorescent probes. (c) The stress-induced alignment and maturation of these cardiac microtissues can also be accurately simulated to inform future design considerations for these tissues. Adapted, with permission, from [83, 86] .
and further improved tissue remodelling and physiological responses via electromechanical stimulation. Furthermore, the stress-induced alignment and maturation of these tissues could be accurately simulated (Fig. 4c ). Robust cardiomyocyte derivation from human induced pluripotent stem cells (iPSC-CM) has also been achieved through the canonical Wnt pathway [84] and, as such, represents an accessible and reproducible cell source that has been successfully utilised to generate myocardial tissue models. An iPSC-CM-based 3D tissue model of long QT syndrome demonstrated increased drug-induced cardiac toxicity and increased arrhythmic signs in the 3D tissue model versus the current industry standard 2D model, thus highlighting the inadequacies of current standard models for risk estimation [85] . An interesting approach to cardiac disease modelling is the combination of cardiac microtissues with microfluidic-based systems to potentially increase throughput and reduce future assay costs [87] . Such a system was utilised effectively to create a 3D pathophysiological model of Barth's syndrome, an X-linked genetic disorder characterised by cardiomyopathy, by first generating iPSC-CMs from patients with Barth's syndrome [88] . This 3D disease model was then incorporated into a microfluidic-based heart-on-a-chip platform, where the functional characteristics of the disease, such as reduced contractile stress, were accurately reproduced before correction of the disease-causing gene TAZ with modRNA therapy to restore contractile function [88] . The power of in vitro pathophysiological models can be enhanced via CRISPR/ Cas9 genome editing to generate isogenic human cell line controls that reproduce disease state phenotypes, and arguably represents the next step in the field [89] .
Cardiotoxicity is of major concern to myocardial tissue, with many drugs having been pulled from market because of this issue, including anticancer drugs [90] , diabetes drugs, and even those targeting CVD itself [91] . To overcome this difficulty, there has been an increasing switch towards utilising human cells to create complex in vitro tissue models as platforms for drug testing. Cardiotoxicity can be induced by anthracyclines, such as doxorubicin, or more targeted therapies, such as HER2 inhibitors (e.g. trastuzumab) used for breast cancers. Furthermore, the proarrhythmic effect of drugs on cardiac tissue has been effectively modelled by Davis et al. [92] . Although there is a clear need for the utilisation of cardiac tissue for drug safety and efficacy testing, the mechanism of cardiac drug action could be determined with 3D myocardium models. For example, one of the mechanisms of action of atorvastatin was only determined through the use of a 3D myocardial tissue model in 2006, yet the drug had been utilised clinically for a decade previous to this study [93] . With increasing activity in the development of advanced therapeutics utilising approaches such as gene therapy and miRNA delivery, these novel in vitro assays could soon become one of the gold standards for safety, efficacy, and mechanistic studies for cardiac applications.
State-of-the-art and future directions
The field of tissue engineering is developing biomimetic biomaterial scaffolds that are showing increasing therapeutic potential for the repair of cardiovascular tissues. However, because of the greater correlation between these models and the physiological conditions found in the in vivo environment, a major opportunity exists to use them as in vitro 3D models for the study of cardiovascular structures and disease interventions. These in vitro models can help span the gap between 2D culture and in vivo testing, thus reducing the cost, time, and ethical burden of current approaches. The use of biomaterials as 3D models to facilitate greater understanding of CVD tissues can build upon other cutting-edge approaches, including miniaturised in vitro 3D microfluidics models, such as organs-on-a-chip, which facilitate fast repeatable results, while minimising cost and waste [90, 94] . Combining multiple tissue models to create a 'body-on-a-chip system' is seen by many to be the ultimate goal to replicate the complex multiorgan crosstalk and reactions observed in vivo [95] . However, the biological complexity of these systems is often comparatively simple compared with the multi-layered and multicellular macroscale tissue-engineered constructs currently being developed in the regenerative medicine field [96] . Increased translation of native tissue complexity into the micron scale used within microfluidic platforms might allow greater correlation between these in vitro testing platforms and native tissues. However, not all testing needs to be completed in a lab-based setting and often the effect of multiple parameters can be projected using in silico simulations. A recent review in this journal profiled the work being completed using in silico models of adverse drug reactions, various protein targets, and gene expression markers to facilitate drug screening in vitro [97] . This work could be augmented and further validated using the proposed in vitro 3D models discussed here leading to powerful and safe drug screening methods.
Although the advantages of in vitro 3D models have been outlined here, there are situations where in vivo animal models remain indispensable, because of the shared pathogenesis and multiple manifestations of different diseases [98] . For example, Marfan Syndrome is well represented using mutagenic mouse models deficient in fibrillin 1 and these models have aided in the discovery of new drug-based treatments to curb the progression of the disease [99, 100] ; the progression of bicuspid aortic valve disease is also well replicated using mutagenic mice, which enable the natural progression of multiple pathologies, something even the most accurate in vitro 3D model of an individual cardiovascular component cannot achieve [98] .
Concluding remarks
In summary, we propose that tissue-engineered biomimetic biomaterial scaffolds can not only serve a therapeutic in regenerating damaged or diseased organs and tissues, but also enable more robust testing of new technologies before in vivo testing. Increased collaboration between pharmaceutical and medical device companies with tissue-engineering researchers could see further development and validation of these models, facilitating a universally beneficial more efficient, safe, and ethical route to market for new devices, drugs, and combination products.
